Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

New 24 well pyrosequencing system handles low sample numbers

Biotage : 01 April, 2008  (New Product)
Pyrosequencing, a subsidiary of Biotage, has launched PyroMark Q24 the latest in the range of pyrosequencing systems.
The new high-performance platform includes a complete software package for the study of genetic and epigenetic variation of genes, providing CpG methylation allele quantification and mutation analysis. These studies are used for a wide range of clinical research, for example the identification and tracking of changes involved in various forms of cancer.

Studying these changes using Pyrosequencing technology, which is based on the principals of sequencing by synthesis, is an ideal choice for genetic analysis in clinical research. The output information is based on real sequence data providing integrated quality control and security in the quality of the results.

The system, aimed at lower throughput needs, optimises the management of fewer samples. The 24 well plate format and the ability to run and analyse both mutation and methylation assays on the same plate provides an ideal solution for managing low sample numbers or mixed analysis needs while providing the accuracy, flexibility and convenience offered by Pyrosequencing technology.

Until now Pyrosequencing technology has only been available in higher throughput systems, placing it out of the reach of many researchers. 'With the introduction of the new PyroMark Q24 system we plan to open up the availability of Pyrosequencing technology to many more researchers.' Said Torben Jorgensen, president and chief executive officer of Biotage.

The PyroMark Q24 performance has been successfully demonstrated at sites in the USA and Europe. Pyromark Q24 was shown to provide reproducible and reliable results at the Dept of Pathology, Uppsala University Hospital for clinical diagnostics in oncology.

According to Jakob Lindmark, vice president sales and marketing for Biosystems unit at Biotage the PyroMark Q24 is the first in a series of solutions for different applications in this lower throughput format.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo